Human IgG antibody Laboratories manufactures the cynomolgus monkey cross-reactive antibody 4-1bb reagents distributed by Genprice. The Cynomolgus Monkey Cross-Reactive Antibody 4-1Bb reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact monkey Antibody. Other Cynomolgus products are available in stock. Specificity: Cynomolgus Category: Monkey Group: Cross-Reactive Antibody
Cross-Reactive Antibody information
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V8061SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V8353-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: CD137 (4-1BB), a member of the tumor necrosis factor receptor superfamily, is a type I transmembrane glycoprotein expressed on the cell surface of activated splenic T cells and thymocytes. The functions of CD137 in T lymphocytes include regulating activation, proliferation and apoptosis. CD137 and CD28 are costimulatory molecules of T cell activation. Costimulatory molecules are important in initiating anti-tumor immune responses. CD137 plays an important role in regulating T-cell-dependent immune responses. Expression of CD137 correlates negatively with lymphocyte proliferation and positively with the degree of activation-induced cell death caused by mitogen overstimulation. In monocytes, CD137 induces activation, promotes adherence and prolongs survival. The LOB12.3 antibody is an agonistic antibody that has been shown to stimulate 4-1BB signaling and delay tumor growthin vivowhen administered in combination with immune checkpoint inhibitors. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V8353-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: CD137 (4-1BB), a member of the tumor necrosis factor receptor superfamily, is a type I transmembrane glycoprotein expressed on the cell surface of activated splenic T cells and thymocytes. The functions of CD137 in T lymphocytes include regulating activation, proliferation and apoptosis. CD137 and CD28 are costimulatory molecules of T cell activation. Costimulatory molecules are important in initiating anti-tumor immune responses. CD137 plays an important role in regulating T-cell-dependent immune responses. Expression of CD137 correlates negatively with lymphocyte proliferation and positively with the degree of activation-induced cell death caused by mitogen overstimulation. In monocytes, CD137 induces activation, promotes adherence and prolongs survival. The LOB12.3 antibody is an agonistic antibody that has been shown to stimulate 4-1BB signaling and delay tumor growthin vivowhen administered in combination with immune checkpoint inhibitors. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V8353SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: CD137 (4-1BB), a member of the tumor necrosis factor receptor superfamily, is a type I transmembrane glycoprotein expressed on the cell surface of activated splenic T cells and thymocytes. The functions of CD137 in T lymphocytes include regulating activation, proliferation and apoptosis. CD137 and CD28 are costimulatory molecules of T cell activation. Costimulatory molecules are important in initiating anti-tumor immune responses. CD137 plays an important role in regulating T-cell-dependent immune responses. Expression of CD137 correlates negatively with lymphocyte proliferation and positively with the degree of activation-induced cell death caused by mitogen overstimulation. In monocytes, CD137 induces activation, promotes adherence and prolongs survival. The LOB12.3 antibody is an agonistic antibody that has been shown to stimulate 4-1BB signaling and delay tumor growthin vivowhen administered in combination with immune checkpoint inhibitors. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V7531-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V7531-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V7531IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V7531SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V7567-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V7567-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V7567BTN | NSJ Bioreagents | 500 ul | EUR 499 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V7567IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V7567SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V8636-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V8636-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
CD137 Antibody / 4-1BB / TNFRSF9 |
|||
V8636SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
Description: CD137 belongs to the tumor necrosis factor receptor family and delivers a costimulatory signal to T lymphocytes. It is expressed on activated T cells and binds an inducible ligand that is found on B cells, macrophages and dendritic cells. Interactions between CD137 and its ligand are involved in antigen presentation and the generation of cytotoxic T cells. CD137 antibody may improve cancer treatment, and has been implicated in breast cancer, melanoma and lymphoma. |
Ubiquitin Cross Reactive Protein (UCRP) Polyclonal Antibody (Pig) |
|||
4-PAL630Hu01 | Cloud-Clone |
|
|
Description: A Rabbit polyclonal antibody against Pig Ubiquitin Cross Reactive Protein (UCRP) |